In the most recent trading session, Zoetis (ZTS) closed at $74.81, indicating a +2.37% shift from the previous trading day.

Zoetis Inc. on Wednesday asked a Pennsylvania federal court to enforce a confidential settlement with the owners of a 3-year-old racehorse that they alleged died after receiving one of Zoetis' antibiotics, saying the plaintiffs can't ignore the agreement and their own counsel.

Organic revenue declined 1% to $2.5 billion, with adjusted net income down 2% to $781 million. US Companion Animal revenue fell 11%, driven by lower clinic visits and intense competition in dermatology and parasiticides. Livestock segment grew 11% globally, with US Livestock surging 23% due to screwworm-related demand and cattle strength. Full-year organic revenue guidance revised to a decline of 3% to 1%, reflecting persistent market pressures. Leadership reshuffle announced with Jay Zakara joining as CFO and COO to drive operational efficiency.

Zoetis (ZTS) reached $69.1 at the closing of the latest trading day, reflecting a -1.05% change compared to its last close.

Zoetis Inc. (NYSE:ZTS) has built one of the strongest franchises in animal health. Its products are used by veterinarians around the world; its portfolio spans medicines, vaccines, and diagnostics, and its research capabilities have helped establish entire categories of treatment. But a moat is only valuable if it protects market share and pricing power when […]